P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

• M. Dimopoulos,
• S. Opat,
• S. D’Sa,
• W. Jurczak,
• H.-P. Lee,
• G. Cull,
• R. G. Owen,
• P. Marlton,
• B. E. Wahlin,
• R. Garcia-Sanz,
• H. McCarthy,
• S. Mulligan,
• A. Tedeschi,
• J. J. Castillo,
• J. Czyz,
• C. Fernandez De Larrea Rodriguez,
• D. Belada,
• E. Libby,
• J. Matous,
• M. Motta,
• T. Siddiqi,
• M. Tani,
• M. Trneny,
• M. Minnema,
• C. Buske,
• V. Leblond,
• S. P. Treon,
• J. Trotman,
• W. Y. Chan,
• J. Schneider,
• H. Allewelt,
• A. Cohen,
• J. Huang,
• C. S. Tam

Affiliations

M. Dimopoulos

1 National and Kapodistrian University of Athens, Athens, Greece

S. Opat

2 Monash Health and Monash University, Clayton, Victoria, Australia

S. D’Sa

3 Centre for Waldenström’s Macroglobulinemia and Associated Disorders, University College London Hospital Foundation Trust, London, United Kingdom

W. Jurczak

4 Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland

H.-P. Lee

5 Flinders Medical Centre, Adelaide, SA

G. Cull

6 Sir Charles Gairdner Hospital, University of Western Australia, Perth, WA, Australia

R. G. Owen

7 St. James University Hospital, Leeds, United Kingdom

P. Marlton

8 Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia

B. E. Wahlin

9 Karolinska Universitetssjukhuset and Karolinska Institutet, Stockholm, Sweden

R. Garcia-Sanz

10 Hospital Universitario de Salamanca, Salamanca, Spain

H. McCarthy

11 Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom

S. Mulligan

12 Royal North Shore Hospital, Sydney, New South Wales, Australia

A. Tedeschi

13 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

J. J. Castillo

14 Dana-Farber Cancer Institute, Boston, MA, United States of America

J. Czyz

15 Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland

C. Fernandez De Larrea Rodriguez

16 Hospital Clinic de Barcelona, Barcelona, Spain

D. Belada

17 FN Hradec Kralove, Hradec Králové, Czechia

E. Libby

18 University of Washington/Seattle Cancer Care Alliance - Clinical Research, Seattle, WA

J. Matous

19 Colorado Blood Cancer Institute, Denver, CA, United States of America

M. Motta

20 AO Spedali Civili di Brescia, Lombardia, Italy

T. Siddiqi

21 City of Hope National Medical Center, Duarte, CA, United States of America

M. Tani

22 Ospedale Civile S.Maria delle Croci, AUSL Ravenna, Italy

M. Trneny

23 Vseobecna fakultni nemocnice v Praze, Prague, Czechia

M. Minnema

24 University Medical Center Utrecht, Utrecht, Netherlands

C. Buske

25 CCC Ulm - Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany

V. Leblond

26 Sorbonne University, Pitié Salpêtrière Hospital, Paris, France

S. P. Treon

14 Dana-Farber Cancer Institute, Boston, MA, United States of America

J. Trotman

27 Concord Repatriation General Hospital, Sydney, New South Wales, Australia

W. Y. Chan

28 BeiGene USA, Inc., San Mateo, CA, United States of America

J. Schneider

28 BeiGene USA, Inc., San Mateo, CA, United States of America

H. Allewelt

28 BeiGene USA, Inc., San Mateo, CA, United States of America

A. Cohen

28 BeiGene USA, Inc., San Mateo, CA, United States of America

J. Huang

28 BeiGene USA, Inc., San Mateo, CA, United States of America

C. S. Tam

29 Royal Melbourne Hospital, Parkville, Victoria, Australia